Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SEC charges former NBTY counsel

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Securities & Exchange Commission filed insider trading charges against former NBTY associate general counsel Mitchell Drucker and his father Ronald Drucker March 2, the commission announces. According to the complaint filed in federal court for the southern district of New York, Mitchell Drucker sold of all his NBTY stock on Oct. 18, 2001 after learning that the firm's fourth-quarter earnings would be 50% lower than analysts had previously predicted. The information was not publicly released until the following day. Mitchell Drucker also instructed his father to sell his shares and oversaw the sale of all of a friend's shares in the firm. Mitchell and Ronald Drucker avoided losses of $138,174 and $51,116, respectively. In addition to the disgorgement of losses avoided and civil penalties, SEC also is asking that the court bar Mitchell Drucker from acting as an officer or director of a public company...

You may also be interested in...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts